Combined modality therapy in NSCLC

Annals of Oncology

Volumn 11, Issue SUPPL. 3, 2000, Pages 85-95

  Eberhardt, W ^a   Bildat, S ^a   Korfee, S ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CARBOPLATIN; CISPLATIN; CYCLOSPORIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; LEVAMISOLE; LOMUSTINE; MITOMYCIN; MITOMYCIN C; NAVELBINE; PACLITAXEL; RADIOSENSITIZING AGENT; UFT; VINDESINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT INDICATION;

EID: 0033778495     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/11.suppl_3.85     Document Type: Conference Paper

References (69)

1. Cancer mortality in Europe, 1990-1994, and an overview of trends from 1955 to 1994
2. Revisions in the international system for staging lung cancer
3. Non-small cell lung cancer
4. Combined modality treatment for locally advanced non-small cell lung cancer
5. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
6. Pretreatment minimal staging and prognostic factors for non-small cell lung cancer
7. Stage category of non-small cell lung cancer: A new proposal
8. Survival of patients with resected N2 non small cell lung cancer (NSCLC): Heterogeneity of prognosis and evidences for a subclassification
9. 'Tumour volume' as a predictor of survival after resection of non-small-cell lung cancer
10. Extent of chest wall invasion and survival in patients with lung cancer
11. Molecular genetic characteristics of lung cancer - Useful as 'real tumor markers'?
12. Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer
13. Criteria of functional operability in patients with bronchial carcinoma: Preoperative assessment of risk and prediction of postoperative function
14. Adjuvant and induction chemotherapy in non-small cell lung cancer
15. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large cell undifferentiated carcinoma
16. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group
17. Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: A randomized study
18. Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer. Results of a randomized prospective study. The Japan Clinical Oncology Group
19. Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): A randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG)
20. Chemotherapy in Non-Small Cell Lung Cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
21. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology
22. Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIa Non-Small Cell Lung Cancer: An Intergroup trial (E 3590)
23. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: Results of the Toronto Phase II Trial
24. A Phase II trial of combined chemotherapy and surgery in stage IIIa non-small cell lung cancer
25. Neoadjuvant therapy for surgically staged IIIa (N2) non-small cell lung cancer
26. 2) in stage III a (N2) Non Small Cell Lung Cancer (NSCLC)
27. Preoperative chemotherapy for stage IIIa (N2) lung cancer: The Sloan-Kettering experience with 136 patients
28. Long-term results of neoadjuvant ifosfamide, cisplatin, and etoposide combination in locally advanced non-small-cell lung cancer
29. Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group
30. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: A 7-year assessment of a randomized controlled trial
31. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone inresectable stage IIIa non-small-cell lung cancer
32. A Phase III comparison of 'best locoregional therapy' with or without chemotherapy for stage IIIa T1-3N2 non-small cell lung cancer: Preliminary results
33. Randomized trial of neoadjuvant therapy for lung cancer: Interim analysis
34. Phase III trial of neoadjuvant chemotherapy in resectable stage I (except T1N0), II, IIIa Non-Small Cell Lung Cancer: The French experience
35. Induction chemotherapy before surgery for early-stage lung cancer: A novel approach
36. Postoperative radiotherapy in non-small-cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomised controlled trials
37. Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial
38. Radiotherapy alone versus combined chemotherapy and radiotherapy inunresectable non-small cell lung carcinoma
39. Inoperable non-small cell lung cancer: Radiation with or without chemotherapy
40. 3rd Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
41. Phase-III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small cell lung cancer: A Hoosier Oncology group protocol
42. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer
43. Hyperfractionated radiation therapy with or without concurrent low-dose dally carboplatin/etoposide for stage III non-small-cell lung cancer: A randomized study
44. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer
45. A randomized clinical trial comparing radiation therapy vs. radiation therapy plus cis-dichlorodiammine platinum (II) in the treatment of locallyadvanced non-small cell lung cancer
46. Radiotherapy enhanced by cis-platinum in stage III non-small cell lung cancer: A phase II study
47. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: Final report of an Australian multi-centre trial
48. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: A phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group
49. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
50. A randomized phase-II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy and concomitant chemoradiotherapy for unresectable stage III non-small cell lung cancer
51. Concurrent cisplatin/etoposide plus radiotherapy for pathologic stage IIIB non-small cell lung cancer: A Southwest Oncology Group phase II study (S9019)
52. Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer
53. Combined-morality treatment of locally advanced non-small cell lung cancer: Incorporation of novel chemotherapeutic agents
54. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer
55. Concurrent radiochemotherapy for patients with stage III non-small-cell lung cancer (NSCLC): Long-term results of a phase II study
56. A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small cell lung cancer: A five-year follow-up report
57. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multicentre trial. CHART Steering committee
58. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
59. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805
60. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer
61. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced Non-Small-Cell Lung Cancer: Mature results of a phase II trial
62. Pre-operative chemoradiotherapy in non-small cell lung cancer stage III patients. Feasibility, toxicity and long-term results of a phase II study
63. Results of surgical resection in stage IIIB Non-Small Cell Lung Cancer after concommittant induction chemoradiotherapy
64. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: Report of a Cancer and Leukemia Group B phase II study
65. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer
66. Randomized trial of chemotherapy and twice-daily irradiation versus chemotherapy alone before surgery in stage III non-small cell lung cancer: Interim analysis of toxicity
67. 'Minimal N2-disease' (operable) stage IIIa non-small cell lung cancer: Prospectively randomized multicenter German phase-III trial of surgery followed by adjuvant radiotherapy versus 'trimodality treatment' - Early results of feasibility and toxicity in this setting
68. Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: Long-term follow-up and investigations of late neuropsychologic effects